MegaPro Biomedical Co., Ltd.
TTPEX:682716.10
TWD
+1.65
(+11.42%)
ISIN
TW0006827009
Return %
Stock
S&P 500
1Y
-5.29
14.20
3Y
-29.22
81.12
5Y
-46.11
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Hsien Chih Wang
- Full Time Employees
- 26
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 66, Shengyi 5th Rd. Hsinchu Taiwan 302
- IPO Date
- Oct 19, 2021
- Website
- megaprobio.com
- Similar Companies
- Business
- MegaPro Biomedical Co., Ltd. is a biotechnology company specializing in the development of niche nano drugs, with a focus on nanoparticle and nanocell technology platforms. The company's main products include MPB-1523, a magnetic resonance imaging (MRI) contrast agent for hepatocellular carcinoma currently in Phase II clinical trials; MPB-1514, a non-sugar iron oxide injection in Phase II clinical trials targeting iron deficiency anemia; MPB-1734, a new formulation anticancer drug in preclinical development; and MPB-2043, an MRI contrast agent for lymph node staging in head and neck squamous cell carcinoma undergoing investigator-initiated trials. MegaPro also leverages PEGylation technology and cell and molecular imaging technology platforms for drug development. Founded in 2014 and headquartered in Zhubei, Taiwan, the company operates primarily within the biotech sector focusing on clinical trial stages and strategic partnerships rather than mass drug manufacturing. In the last 1-2 years, MegaPro Biomedical has made significant advancements by completing a capital increase and introducing new strategic partners, including China Chemical & Pharmaceutical Co., which has engaged in strategic collaboration and equity investment to advance product development and commercialization. The company has achieved important clinical milestones such as passing the US FDA phase II end-of-phase meeting for MPB-1523 and advancing plans for Phase III trials, as well as completing initial patient admissions for MPB-2043 clinical trials in Taiwan. MegaPro continues to collaborate internationally, for example with Stanford University on MRI contrast agents for stem cell and immune cell therapy, while also developing magnetic hyperthermia therapy in partnership with domestic academic institutions. These efforts signal a strategic emphasis on innovative nano drug development and clinical validation to expand its product pipeline and market reach in Taiwan and globally. MegaPro Biomedical positions itself as a technology-driven firm focused on pharmaceutical innovation in niche markets including oncology, anemia treatment, and diagnostic imaging enhancement. Its business model involves partnering with domestic API and drug formulation manufacturers for clinical drug supply, while it drives R&D and clinical trial activities. The company targets healthcare providers, pharmaceutical collaborators, and researchers, operating primarily within Taiwan but aiming for global regulatory approvals, including FDA interactions for orphan drug designations. Its strategic alliances and recent funding rounds have strengthened its capability to commercialize novel nano drug products and expand its presence in the biotechnology and pharmaceutical industries.